4 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 4 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Not yet recruiting 1 |
Follow VP-102: new trials by email Literature Review of VP-102 trials Research Report on VP-102
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5) VP-102 - Common Warts, Common Warts (Verruca Vulgaris) | Phase 2 | Not yet recruiting | Verrica Pharmaceuticals Inc. | 30 | 2026-10-01 | 2026-10-20 |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan) - Common Warts, Common Warts (Verruca Vulgaris) | Phase 3 | Recruiting | Verrica Pharmaceuticals Inc. | 300 | 2026-06-15 | 2026-09-03 |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) VP-102, Vehicle - Common Warts, Common Warts (Verruca Vulgaris) | Phase 3 | Active not recruiting | Verrica Pharmaceuticals Inc. | 302 | 2025-12-17 | 2026-10-23 |
| A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts VP-102 and applicator, Placebo - Condylomata Acuminata, Papillomavirus Infections | Phase 2 | Completed | Verrica Pharmaceuticals Inc. | 105 | 2019-06-25 | 2024-11-27 |
| Cantharidin Application in Molluscum Patients-1 VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102 - Molluscum Contagiosum | Phase 3 | Completed | Verrica Pharmaceuticals Inc. | 266 | 2018-03-21 | 2022-01-11 |
| Cantharidin Application in Molluscum Patients VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102 - Molluscum Contagiosum | Phase 3 | Completed | Verrica Pharmaceuticals Inc. | 262 | 2018-02-14 | 2021-12-14 |
| Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. VP-102 with applicator - Molluscum Contagiosum | Phase 2 | Completed | Verrica Pharmaceuticals Inc. | 33 | 2017-06-08 | 2021-08-11 |
Warts (4) · Molluscum Contagiosum (3) · Skin Diseases (3) · Skin Diseases, Viral (3) · Cellulitis (2) · Poxviridae Infections (2) · Condylomata Acuminata (1) · Papillomavirus Infections (1) · Sexually Transmitted Diseases (1) · Sexually Transmitted Diseases, Viral (1) · Skin Diseases, Infectious (1) · Virus Diseases (1)
Verrica Pharmaceuticals Inc. (7)
United States (7) · Japan (1)
Lawrence Eichenfield, MD (2) · Gary Goldenberg, MD (1) · Scott Guenthner, MD (1)
PMID 32965495, PMID 33599960, PMID 34976290, PMID 33400412, PMID 34515985